RU2313343C2 - Комплекс включения s-омепразола (эсомепразола) с циклодекстрином - Google Patents
Комплекс включения s-омепразола (эсомепразола) с циклодекстрином Download PDFInfo
- Publication number
- RU2313343C2 RU2313343C2 RU2003137221/15A RU2003137221A RU2313343C2 RU 2313343 C2 RU2313343 C2 RU 2313343C2 RU 2003137221/15 A RU2003137221/15 A RU 2003137221/15A RU 2003137221 A RU2003137221 A RU 2003137221A RU 2313343 C2 RU2313343 C2 RU 2313343C2
- Authority
- RU
- Russia
- Prior art keywords
- omeprazole
- cyclodextrin
- solution
- inclusion complex
- complex
- Prior art date
Links
- 229960000381 omeprazole Drugs 0.000 title claims abstract description 55
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 40
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract description 25
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 title 1
- 229960004770 esomeprazole Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000243 solution Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004327 boric acid Substances 0.000 claims abstract description 7
- 239000012670 alkaline solution Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000002955 isolation Methods 0.000 claims abstract description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 11
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 11
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 11
- 229960004853 betadex Drugs 0.000 claims description 11
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 208000018556 stomach disease Diseases 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010057969 Reflux gastritis Diseases 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 208000000689 peptic esophagitis Diseases 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 11
- 238000010790 dilution Methods 0.000 abstract description 4
- 239000012895 dilution Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000029219 regulation of pH Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 13
- 150000001556 benzimidazoles Chemical class 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 235000011121 sodium hydroxide Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- -1 alkaline earth metal salts Chemical class 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 3
- 229960003174 lansoprazole Drugs 0.000 description 3
- 229960004157 rabeprazole Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000004684 trihydrates Chemical class 0.000 description 3
- IQPSEEYGBUAQFF-SANMLTNESA-N 6-(difluoromethoxy)-2-[(s)-(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound COC1=CC=NC(C[S@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-SANMLTNESA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0113792A GB2376231A (en) | 2001-06-06 | 2001-06-06 | Benzimidazole-cyclodextrin inclusion complex |
| GB0113792.6 | 2001-06-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003137221A RU2003137221A (ru) | 2005-06-10 |
| RU2313343C2 true RU2313343C2 (ru) | 2007-12-27 |
Family
ID=9916040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003137221/15A RU2313343C2 (ru) | 2001-06-06 | 2002-06-06 | Комплекс включения s-омепразола (эсомепразола) с циклодекстрином |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040147481A1 (enExample) |
| EP (1) | EP1401442B1 (enExample) |
| JP (1) | JP2004536810A (enExample) |
| AT (1) | ATE282412T1 (enExample) |
| AU (1) | AU2002344386B2 (enExample) |
| CA (1) | CA2449769C (enExample) |
| DE (1) | DE60201995T2 (enExample) |
| ES (1) | ES2232780T3 (enExample) |
| GB (1) | GB2376231A (enExample) |
| LT (1) | LT5182B (enExample) |
| LV (1) | LV13154B (enExample) |
| NZ (1) | NZ529956A (enExample) |
| PL (1) | PL366940A1 (enExample) |
| PT (1) | PT1401442E (enExample) |
| RU (1) | RU2313343C2 (enExample) |
| WO (1) | WO2002098423A1 (enExample) |
| ZA (1) | ZA200309841B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1707217A1 (en) | 2004-12-17 | 2006-10-04 | Wacker Chemie AG | Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared |
| US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| CA2631459A1 (en) | 2005-12-28 | 2007-07-05 | Union Quimico Farmaceutica, S.A. | A process for the preparation of the (s)-enantiomer of omeprazole |
| KR20070069567A (ko) * | 2005-12-28 | 2007-07-03 | 에스케이케미칼주식회사 | 저장안정성이 우수한 ｓ-오메프라졸 함유 포접 복합체 및이의 제조방법 |
| PT2106397E (pt) | 2007-09-25 | 2012-01-23 | Hetero Drugs Ltd | Processo para a preparação de esomeprazol enantiomericamente puro |
| WO2010097583A1 (en) * | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
| CN104277030B (zh) * | 2013-07-03 | 2016-04-20 | 湖南理工学院 | 一种反应萃取分离泮托拉唑对映体的方法 |
| CN103768028A (zh) * | 2014-01-15 | 2014-05-07 | 山东新时代药业有限公司 | 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2105773C1 (ru) * | 1991-12-31 | 1998-02-27 | Санкионг Индастриз Ко., Лтд. | Способ получения стабильных в кислой среде производных бензимидазола |
| RU2137766C1 (ru) * | 1993-05-28 | 1999-09-20 | Астра Актиеболаг | Оптически чистые na+, mg2+, li+, k+ или са2+ соли (-)-5-метокси-2[[(4-метокси-3,5-диметил-2-пиридинил)метил] сульфинил]-1h-бензимидазола, способ их получения, фармкомпозиция на их основе и промежуточное соединение |
| WO2001014367A1 (en) * | 1999-08-26 | 2001-03-01 | Applied Analytical Industries, Inc. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3427787A1 (de) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel |
| US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
| SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| JPH0948730A (ja) * | 1995-06-02 | 1997-02-18 | Takeda Chem Ind Ltd | 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物 |
| AU5780696A (en) * | 1995-06-02 | 1996-12-18 | Takeda Chemical Industries Ltd. | Stabilized composition comprising an antiulcerative benzimid azole |
| SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| CA2282513C (en) * | 1997-03-13 | 2007-09-18 | Hexal Ag | Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
| EP1018340B1 (en) * | 1999-01-06 | 2003-09-10 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them |
| EP1206466B1 (en) * | 1999-08-26 | 2005-10-12 | aaiPharma Inc. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| SE9903831D0 (sv) * | 1999-10-22 | 1999-10-22 | Astra Ab | Formulation of substituted benzimidazoles |
-
2001
- 2001-06-06 GB GB0113792A patent/GB2376231A/en not_active Withdrawn
-
2002
- 2002-06-06 RU RU2003137221/15A patent/RU2313343C2/ru not_active IP Right Cessation
- 2002-06-06 EP EP02776528A patent/EP1401442B1/en not_active Expired - Lifetime
- 2002-06-06 PL PL02366940A patent/PL366940A1/xx not_active Application Discontinuation
- 2002-06-06 JP JP2003501462A patent/JP2004536810A/ja active Pending
- 2002-06-06 WO PCT/GB2002/002542 patent/WO2002098423A1/en not_active Ceased
- 2002-06-06 ES ES02776528T patent/ES2232780T3/es not_active Expired - Lifetime
- 2002-06-06 CA CA2449769A patent/CA2449769C/en not_active Expired - Fee Related
- 2002-06-06 NZ NZ529956A patent/NZ529956A/en unknown
- 2002-06-06 DE DE60201995T patent/DE60201995T2/de not_active Expired - Lifetime
- 2002-06-06 AU AU2002344386A patent/AU2002344386B2/en not_active Ceased
- 2002-06-06 PT PT02776528T patent/PT1401442E/pt unknown
- 2002-06-06 US US10/479,658 patent/US20040147481A1/en not_active Abandoned
- 2002-06-06 AT AT02776528T patent/ATE282412T1/de not_active IP Right Cessation
-
2003
- 2003-12-03 LT LT2003100A patent/LT5182B/lt not_active IP Right Cessation
- 2003-12-19 ZA ZA200309841A patent/ZA200309841B/en unknown
-
2004
- 2004-01-06 LV LVP-04-01A patent/LV13154B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2105773C1 (ru) * | 1991-12-31 | 1998-02-27 | Санкионг Индастриз Ко., Лтд. | Способ получения стабильных в кислой среде производных бензимидазола |
| RU2137766C1 (ru) * | 1993-05-28 | 1999-09-20 | Астра Актиеболаг | Оптически чистые na+, mg2+, li+, k+ или са2+ соли (-)-5-метокси-2[[(4-метокси-3,5-диметил-2-пиридинил)метил] сульфинил]-1h-бензимидазола, способ их получения, фармкомпозиция на их основе и промежуточное соединение |
| WO2001014367A1 (en) * | 1999-08-26 | 2001-03-01 | Applied Analytical Industries, Inc. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2232780T3 (es) | 2005-06-01 |
| CA2449769A1 (en) | 2002-12-12 |
| LV13154B (en) | 2004-07-20 |
| US20040147481A1 (en) | 2004-07-29 |
| CA2449769C (en) | 2010-12-14 |
| DE60201995T2 (de) | 2005-11-24 |
| ATE282412T1 (de) | 2004-12-15 |
| GB0113792D0 (en) | 2001-07-25 |
| EP1401442A1 (en) | 2004-03-31 |
| HK1064602A1 (en) | 2005-02-04 |
| ZA200309841B (en) | 2005-03-14 |
| LT2003100A (en) | 2004-09-27 |
| NZ529956A (en) | 2005-07-29 |
| JP2004536810A (ja) | 2004-12-09 |
| LT5182B (lt) | 2004-12-27 |
| PL366940A1 (en) | 2005-02-07 |
| AU2002344386B2 (en) | 2006-11-30 |
| EP1401442B1 (en) | 2004-11-17 |
| DE60201995D1 (de) | 2004-12-23 |
| WO2002098423A1 (en) | 2002-12-12 |
| PT1401442E (pt) | 2005-02-28 |
| GB2376231A (en) | 2002-12-11 |
| RU2003137221A (ru) | 2005-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60020967T2 (de) | Kristalle von lansoprazole | |
| CN1146558C (zh) | 新的邦托拉唑盐 | |
| HUP0400781A2 (hu) | Eljárás (R)- vagy (S)-lansoprazol kristályosítására, az előállított kristályok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP2001507025A (ja) | 新規な化合物形態 | |
| WO2002012225A1 (en) | Salts of benzimidazole compound and use thereof | |
| DE69911159T2 (de) | Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen | |
| JP2012246316A (ja) | エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法 | |
| KR100619200B1 (ko) | 개선된 화학적 제조 방법 및 제약 제형 | |
| EP1401442B1 (en) | S-omeprazole (esomeprazole) inclusion complex with cyclodextrins | |
| AU2002344386A1 (en) | S-omeprazole (esomeprazole) inclusion complex with cyclodextrins | |
| JP3283252B2 (ja) | ベンズイミダゾール化合物の結晶 | |
| JP2004536810A5 (enExample) | ||
| WO2005070426A1 (en) | Freeze-dried (-)-pantoprazole preparation and (-)-pantoprazole injection | |
| HK1064602B (en) | S-omeprazole (esomeprazole) inclusion complex with cyclodextrins | |
| JP4160293B2 (ja) | 結晶の製造法 | |
| JP2001072675A (ja) | ベンズイミダゾール化合物の結晶 | |
| AU2003247729A1 (en) | A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof | |
| US20090030044A1 (en) | Crystal of Salt of Benzimidazole Compound | |
| JP2008505160A (ja) | （ｓ）−オメプラゾールのマグネシウム塩の固形形態とその製造方法 | |
| JP2001122783A (ja) | ベンズイミダゾール化合物の結晶 | |
| DE10234617A1 (de) | Neues Salz von (S)-Pantoprazol | |
| JPWO2001002389A1 (ja) | ベンズイミダゾール化合物の結晶 | |
| MXPA99005661A (en) | A novel compound form | |
| CH699254B1 (de) | Orale pharmazeutische Formulierung für Pyridylmethylsulfinyl-Benzimidazole, enthaltend Aluminiumoxid, und Verfahren zu ihrer Herstellung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090607 |